Caribou Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.1%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$1.18next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly118.6MTarget: Sufficient to fund operations into 2H 2027
Quarterly Licensing and Collaboration Revenue Quarterly2.4M
Quarterly Net Loss Quarterly25.1M
Watch Items
- Pivotal ANTLER-3 Phase 3 Trial Initiation for Vispa-celTrigger: Start-up activities and patient enrollment initiationAction: Monitor clinical trial registry updates and company press releases for first patient dosed
- CB-011 CaMMouflage Phase 1 Trial Dose Expansion DataTrigger: Initial dose expansion data release expected in 2026Action: Review clinical efficacy (ORR, CR rates) and safety profile updates at upcoming medical conferences
- Cash Runway and Capital Raising ActivitiesTrigger: Cash balance falling below $100 million or runway dropping under 12 monthsAction: Evaluate potential dilutive equity offerings, ATM utilization, or new strategic licensing collaborations
Research as of 20 Jun 2026